These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 9825730

  • 1. Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity.
    Pavillard V, Formento P, Rostagno P, Formento JL, Fischel JL, Francoual M, Etienne MC, Milano G.
    Biochem Pharmacol; 1998 Nov 15; 56(10):1315-22. PubMed ID: 9825730
    [Abstract] [Full Text] [Related]

  • 2. Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines.
    Fischel JL, Rostagno P, Formento P, Dubreuil A, Etienne MC, Milano G.
    Br J Cancer; 2001 Feb 15; 84(4):579-85. PubMed ID: 11207057
    [Abstract] [Full Text] [Related]

  • 3. Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.
    Plasencia C, Abad A, Martinez-Balibrea E, Taron M.
    Invest New Drugs; 2004 Nov 15; 22(4):399-409. PubMed ID: 15292710
    [Abstract] [Full Text] [Related]

  • 4. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity.
    Mullany S, Svingen PA, Kaufmann SH, Erlichman C.
    Cancer Chemother Pharmacol; 1998 Nov 15; 42(5):391-9. PubMed ID: 9771954
    [Abstract] [Full Text] [Related]

  • 5. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.
    Raymond E, Louvet C, Tournigand C, Coudray AM, Faivre S, De Gramont A, Gespach C.
    Int J Oncol; 2002 Aug 15; 21(2):361-7. PubMed ID: 12118332
    [Abstract] [Full Text] [Related]

  • 6. Sequential treatment with SN-38 followed by 5-fluorouracil shows synergistic cytotoxic activity in small cell lung cancer cells.
    Takeda K, Suyama H, Igishi T, Shigeoka Y, Matsumoto S, Yamasaki A, Hashimoto K, Sumikawa T, Morita M, Ueda Y, Shimizu E.
    Oncol Rep; 2008 Apr 15; 19(4):945-51. PubMed ID: 18357380
    [Abstract] [Full Text] [Related]

  • 7. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
    van Triest B, Pinedo HM, van Hensbergen Y, Smid K, Telleman F, Schoenmakers PS, van der Wilt CL, van Laar JA, Noordhuis P, Jansen G, Peters GJ.
    Clin Cancer Res; 1999 Mar 15; 5(3):643-54. PubMed ID: 10100718
    [Abstract] [Full Text] [Related]

  • 8. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
    Nakajima TE, Yasunaga M, Kano Y, Koizumi F, Kato K, Hamaguchi T, Yamada Y, Shirao K, Shimada Y, Matsumura Y.
    Int J Cancer; 2008 May 01; 122(9):2148-53. PubMed ID: 18196580
    [Abstract] [Full Text] [Related]

  • 9. Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines.
    van der Wilt CL, Kuiper CM, Peters GJ.
    Oncol Res; 1999 May 01; 11(8):383-91. PubMed ID: 10803742
    [Abstract] [Full Text] [Related]

  • 10. Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo.
    Guichard S, Cussac D, Hennebelle I, Bugat R, Canal P.
    Int J Cancer; 1997 Nov 27; 73(5):729-34. PubMed ID: 9398054
    [Abstract] [Full Text] [Related]

  • 11. Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine.
    Temmink OH, Hoebe EK, Fukushima M, Peters GJ.
    Eur J Cancer; 2007 Jan 27; 43(1):175-83. PubMed ID: 17049227
    [Abstract] [Full Text] [Related]

  • 12. Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance.
    Xu JM, Azzariti A, Tommasi S, Lacalamita R, Colucci G, Johnston PG, Church SW, Paradiso A.
    Clin Colorectal Cancer; 2002 Nov 27; 2(3):182-8. PubMed ID: 12482336
    [Abstract] [Full Text] [Related]

  • 13. [Irinotecan in combination for colon cancer].
    Ducreux M, Gil-Delgado M, André T, Ychou M, de Gramond A, Khayat D.
    Bull Cancer; 1998 Dec 27; Spec No():43-6. PubMed ID: 9932084
    [Abstract] [Full Text] [Related]

  • 14. Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.
    Paillas S, Boissière F, Bibeau F, Denouel A, Mollevi C, Causse A, Denis V, Vezzio-Vié N, Marzi L, Cortijo C, Ait-Arsa I, Askari N, Pourquier P, Martineau P, Del Rio M, Gongora C.
    Cancer Res; 2011 Feb 01; 71(3):1041-9. PubMed ID: 21159664
    [Abstract] [Full Text] [Related]

  • 15. Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts.
    Na YS, Kim SM, Jung KA, Yang SJ, Hong YS, Ryu MH, Ro S, Cho DH, Kim JC, Jin DH, Lee JS, Kim TW.
    Oncol Rep; 2010 Dec 01; 24(6):1509-14. PubMed ID: 21042746
    [Abstract] [Full Text] [Related]

  • 16. Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients.
    Cecchin E, Corona G, Masier S, Biason P, Cattarossi G, Frustaci S, Buonadonna A, Colussi A, Toffoli G.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 1):6901-7. PubMed ID: 16203781
    [Abstract] [Full Text] [Related]

  • 17. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
    Britten CD, Hilsenbeck SG, Eckhardt SG, Marty J, Mangold G, MacDonald JR, Rowinsky EK, Von Hoff DD, Weitman S.
    Cancer Res; 1999 Mar 01; 59(5):1049-53. PubMed ID: 10070962
    [Abstract] [Full Text] [Related]

  • 18. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line.
    Guichard S, Hennebelle I, Bugat R, Canal P.
    Biochem Pharmacol; 1998 Mar 01; 55(5):667-76. PubMed ID: 9515577
    [Abstract] [Full Text] [Related]

  • 19. Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in a colon cancer cell line.
    Inoue Y, Miki C, Watanabe H, Hiro J, Toiyama Y, Ojima E, Yanagi H, Kusunoki M.
    J Gastroenterol; 2006 Dec 01; 41(12):1149-57. PubMed ID: 17287894
    [Abstract] [Full Text] [Related]

  • 20. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS, Jung KA, Kim SM, Hong YS, Ryu MH, Jang SJ, Moon DH, Cho DH, Kim JC, Lee JS, Kim TW.
    Cancer Chemother Pharmacol; 2011 Aug 01; 68(2):389-98. PubMed ID: 21046105
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.